Related Experiment Video
Updated: Aug 29, 2025

Intra-cardiac Side-Firing Light Catheter for Monitoring Cellular Metabolism using Transmural Absorbance Spectroscopy of Perfused Mammalian Hearts
Published on: May 12, 2019
SGLT2 inhibition reduces myocardial oxygen consumption
Esben Søndergaard1,2, Esben S Lauritzen1, Katrine M Lauritsen1,2
1Steno Diabetes Center, Aarhus, Denmark.
Insights
Sodium-glucose cotransporter 2 (SGLT2) inhibition reduces myocardial oxygen consumption. This finding may explain the cardioprotective effects of SGLT2 inhibitors in patients with cardiac disease.
Area of Science:
- Cardiology
- Metabolic Diseases
- Pharmacology
Background:
- Sodium-glucose cotransporter 2 (SGLT2) inhibition is linked to reduced cardiac disease risk, but mechanisms remain unclear.
- Improved myocardial energetics is a proposed explanation for the cardioprotective effects of SGLT2 inhibitors.
- Previous studies lacked the statistical power to confirm these effects.
Purpose of the Study:
- To investigate the impact of SGLT2 inhibition on myocardial oxygen consumption and external efficiency.
- To leverage pooled data from randomized clinical trials for enhanced statistical power.
Main Methods:
- Meta-analysis of data from two randomized clinical trials.
- Measurement of myocardial oxygen consumption and external efficiency using positron emission tomography.
- Analysis included 59 participants.
Main Results:
- SGLT2 inhibition significantly reduced myocardial oxygen consumption ( -1.06 mL/100g/min; p=0.01).
- No significant effect was observed on myocardial external efficiency (p=0.13).
Conclusions:
- SGLT2 inhibition decreases resting myocardial oxygen consumption.
- This reduction in oxygen demand may contribute to the observed cardioprotective benefits of SGLT2 inhibitors.
Aims/Hypothesis:
SGLT2 inhibition is associated with a reduced risk of cardiac disease that is still largely unexplained. According to one hypothesis, improved myocardial energetics may explain the cardioprotective effects of SGLT2i. However, recent mechanistic studies that have addressed this question have lacked the power to detect discrete but still clinically significant effects.
Methods:
We pooled data from two recent randomized clinical trials and performed a meta-analysis to determine the effect of SGLT2 inhibition on myocardial oxygen consumption and myocardial external efficiency measured by positron emission tomography.
Results:
SGLT2 inhibition reduced myocardial oxygen consumption (-1.06 [95%CI: 0.22-1.89] mL/100 g/min (n = 59, p = 0.01)), but did not affect myocardial external efficiency (2.22 [95%CI: 0.66-5.11] % (n = 59, p = 0.13)).
Conclusions:
/interpretation: SGLT2 inhibition reduces myocardial oxygen consumption at rest, which may contribute to the drugs' cardioprotective effects.
More Related Videos
11:10Respirometric Oxidative Phosphorylation Assessment in Saponin-permeabilized Cardiac Fibers
Published on: February 28, 2011
09:04Skeletal Muscle Neurovascular Coupling, Oxidative Capacity, and Microvascular Function with 'One Stop Shop' Near-infrared Spectroscopy
Published on: February 20, 2018
Related Concept Videos
Pathophysiology of Cardiac Performance
The Electron Transport Chain
Inhibitors of the electron transport chain
Rotenone, a widely used pesticide, prevents electron transfer from Fe-S cluster to ubiquinone or Q...
Feedback Inhibition